SBBP Strongbridge Biopharma plc

5.95
-0.17  -3%
Previous Close 6.13
Open 6.15
Price To book 22.04
Market Cap 213083447
Shares 35,812,344
Volume 189,314
Short Ratio 10.29
Av. Daily Volume 122,177

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrollment from second trial to begin 3Q 2017 with top-line data expected in 3Q 2018.
COR-003 (levoketoconazole) - LOGICS
Endogenous Cushing’s syndrome
Phase 3 completion of enrollment announced June 27, 2017 with top-line data due 2Q 2018.
COR-003 (levoketoconazole) - SONICS
Endogenous Cushing’s syndrome

Latest News

  1. Strongbridge Biopharma plc Announces Closing of Public Offering of Ordinary Shares
  2. Here's Why Strongbridge Biopharma Fell as Much as 20% Today
  3. Strongbridge Biopharma plc Announces Pricing of Public Offering of Ordinary Shares
  4. Strongbridge Biopharma plc Announces Proposed Public Offering of Ordinary Shares
  5. Strongbridge Biopharma plc Launches the Uncovering Periodic Paralysis Genetic Testing Program
  6. What Does Strongbridge Biopharma plc’s (SBBP) Share Price Indicate?
  7. Strongbridge Biopharma plc to Present at the Cantor Fitzgerald Global Healthcare Conference
  8. Strongbridge Biopharma plc to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
  9. Strongbridge Biopharma plc to Present at the Canaccord Genuity 37th Annual Growth Conference
  10. Strongbridge Biopharma reports 2Q loss
  11. Strongbridge Biopharma plc Provides Updates on KEVEYIS® Launch and Recent Business Highlights, and Reports Second Quarter 2017 Financial Results
  12. Investor Network: Strongbridge Biopharma plc to Host Earnings Call
  13. Strongbridge Biopharma (SBBP) Rises: Stock Moves 17% Higher
  14. Strongbridge Biopharma plc to Host Conference Call on August 7, 2017 to Provide KEVEYIS® Launch Update and Report Second Quarter 2017 Financial Results
  15. Strongbridge (SBBP) Shows Strength: Stock Moves Up 10.1%